Taysha Gene Therapies Poised to Take on argenx in the Gene Therapy Market
November 24, 2022
Trending News ☀️
Taysha Gene Therapies ($NASDAQ:TSHA) is a cutting-edge gene therapy company that is poised to take on argenx in the gene therapy market. Both companies have cutting-edge technology and are committed to improving the lives of people with genetic disorders. However, Taysha Gene Therapies has an advantage over argenx because it is a newer company with more flexible and innovative technology. In addition, Taysha Gene Therapies is committed to working with patients and families to ensure that they receive the best possible care.
Share Price
Taysha Gene Therapies is a biotechnology company that is focused on developing gene therapies for rare neurological disorders. The company is currently working on treatments for Rett syndrome, Angelman syndrome, and Batten disease. On Monday, TAYSHA GENE THERAPIES stock opened at $1.6 and closed at $1.6, up by 0.6% from prior closing price of 1.6. The stock has been volatile due to the news sentiment around the company, which has mostly been negative. Live Quote…
About the Company
VI Analysis
The company’s fundamentals reflect its long term potential, and the VI app makes it easy to see this potential. However, based on the VI Risk Rating, TAYSHA GENE THERAPIES is a high risk investment in terms of financial and business aspects. The app has detected 3 risk warnings in the balance sheet, cashflow statement, and non-financial areas. To see these warnings, become a registered user. More…
VI Peers
The Company focuses on developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations. Taysha Gene Therapies Inc’s competitors include uniQure NV, Inozyme Pharma Inc, Sorrento Therapeutics Inc.
– uniQure NV ($NASDAQ:QURE)
UniQure NV is a Dutch holding company that operates in the biopharmaceutical industry. The company researches, develops, and commercializes gene therapies. As of 2022, UniQure NV has a market cap of 884.11M and a Return on Equity of -12.84%. The company’s products are used to treat patients with rare and often fatal diseases.
– Inozyme Pharma Inc ($NASDAQ:INZY)
Inozyme Pharma Inc is a biopharmaceutical company that focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).
Inozyme Pharma Inc has a market cap of 88.72M as of 2022. The company’s Return on Equity is -48.16%. Inozyme Pharma Inc focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).
– Sorrento Therapeutics Inc ($NASDAQ:SRNE)
Sorrento Therapeutics Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases. The company’s market cap is 715.42M as of 2022 and has a return on equity of -190.34%. Sorrento Therapeutics is headquartered in San Diego, California.
Summary
Investing in Taysha Gene Therapies could be a smart move for investors looking to profit from the growing gene therapy market. Taysha is a clinical-stage biotech company developing gene therapies for rare neurological disorders, and is currently one of the leading contenders in the race to develop a treatment for Rett syndrome. Rett syndrome is a rare genetic disorder that primarily affects girls and causes problems with brain development, movement, and speech. There is currently no cure for Rett syndrome, and the only available treatment is symptomatic.
If the drug continues to show positive results in clinical trials, it could potentially be approved by the FDA within the next few years. Investing in Taysha Gene Therapies could be a risky proposition, as the company is still in the early stages of drug development.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
